Erasca, Inc. (ERAS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Erasca, Inc. (ERAS)
Go deeper and ask any question about ERAS
Company Performance
Current Price
as of Sep 17, 2024$2.89
P/E Ratio
N/A
Market Cap
$816.44M
Description
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 1, 2018 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerERAS
- Price$2.89+2.48%
Trading Information
- Market Cap$816.44M
- Float62.08%
- Average Daily Volume (1m)1,846,569
- Average Daily Volume (3m)2,197,206
- EPS-$0.92
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$63.20M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$44.18M
- EV$159.58M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings